Document:

FORM
OF SERIES 1 WARRANT

 

CHANTICLEER
HOLDINGS, INC.

 

	Warrant
    Shares: _______	Initial
    Exercise Date: _______, 2016

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after ______, 2016 (the “Initial Exercise Date”) and on or prior to the close of business on the seventh
year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for
and purchase from Chanticleer Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares of
the Company’s Common Stock, subject to adjustment hereunder, the “Warrant Shares”). This Warrant was
issued as part of a unit, each unit consisting of one Warrant and one share of the Company’s 9% Redeemable Series 1 Preferred
Stock (“Series 1 Preferred”). The shares of Series 1 Preferred and Series 1 Warrants are components of the units,
are not detachable and are not separately transferable. The purchase price of ten (10) shares of Common Stock under this Warrant
shall be equal to the surrender of one share of Series 1 Preferred, the (“Exercise Price”).

 

Section
1. Definitions. Capitalized terms not otherwise defined herein shall have the meanings set forth below:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

    	 	1	 

     

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“SEC
Reports” all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities
Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

“Transfer
Agent” means Securities Transfer Corporation, the current transfer agent of the Company and any successor transfer agent
of the Company.

 

Section
2. Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part (in increments of
ten (10) Warrant Shares, subject to adjustment as provided herein), at any time or times on or after the Initial Exercise Date
and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate
by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed
and completed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto and surrender of applicable
number of shares of Series 1 Preferred for payment of Exercise Price. If shares of Series 1 Preferred are held by Holder in certificated
form, Holder will be required to physically surrender the certificates to the Company for cancellation within three (3) Trading
Days of the applicable Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to
physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of
lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. The Holder, by acceptance of this Warrant, acknowledge s and agrees that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 	2	 

     

    

 

b)
Exercise Price. The exercise price per ten (10) whole shares of the Common Stock under this Warrant shall be equal to the
surrender of one share of Series 1 Preferred, subject to adjustment hereunder (the “Exercise Price”). Exercise
under this Warrant must be made only in increments of ten (10) whole shares of the Common Stock, subject to adjustment as provided
herein.

 

c)
Automatic Exercise. If the Company’s Common Stock trades above $3.00 per share for five consecutive trading days
on the Trading Market, the Series 1 Warrants will automatically be exercised.

 

d)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent
to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company’s share
register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant
to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after
the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). For purposes
of Rule 200 under Regulation SHO of the Securities Act, the Warrant Shares shall be deemed to have been issued, and Holder shall
be deemed for all such purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has
been exercised upon delivery of the Notice of Exercise and for purposes of Delaware corporate law, the Warrant Shares shall be
deemed to have been issued, and Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant
Shares with respect to which this Warrant has been exercised upon delivery of the Notice of Exercise and the aggregate Exercise
Price, irrespective of the date of delivery of the Warrant Shares; provided the Exercise Price and all taxes required to be paid
by the Holder, if any, are received within three (3) Trading Days of delivery of the Notice of Exercise.

 

    	 	3	 

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder.

 

iv.
Closing of Books. The Company will not close its stockholder books or records in any manner that prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

v.
Notice of Automatic Exercise. The Company shall promptly deliver to the Holder by facsimile or email a notice setting forth
a brief statement of the facts triggering such automatic exercise and procedures required to cancel the Warrants and Series 1
Preferred and effect issuance of Warrant Shares, if any.

 

    	 	4	 

     

    

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two (2) Trading
Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect
to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    	 	5	 

     

    

 

Section
3. Certain Adjustments.

 

a)
Stock Splits. If the Company, at any time while this Warrant is outstanding: (i) subdivides outstanding shares of Common
Stock into a larger number of shares, (ii) combines (including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares or (iii) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of
this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.
Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the effective date in the case of a
subdivision, combination or re-classification.

 

b)
Calculations. All calculations under this Section 3 shall be made to the nearest whole share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum
of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

c)
Notice to Holder.

 

i.
Adjustment to Warrant Shares. Whenever the number of Warrant Shares issuable upon exercise of this Warrant is adjusted,
pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting
forth the resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such
adjustment.

 

    	 	6	 

     

    

 

 

Section
4. Transfer of Warrant. This Warrant is part of a unit, each unit consisting of one Series 1 Warrant and one share
of Series 1 Preferred. This Warrant is neither detachable from the Series 1 Preferred nor separately transferable.

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

    	 	7	 

     

    

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the laws of the state of Delaware.

 

f)
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication
is delivered via facsimile or e-mail at or prior to 5:30 p.m. (Eastern City time) on a Trading Day, (b) the next Trading Day after
the date of transmission, if such notice or communication is delivered via facsimile or e-mail on a day that is not a Trading
Day or later than 5:30 p.m. (Eastern time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is
required to be given. The addresses for such notices and communications shall be, for the Company, as set forth in the Company’s
most recent SEC Report or provided by the Company’s Secretary from time to time and, for a Holder, as set forth in the Company’s
books and records, which may be updated by Holder from time to time by notice to the Company’s Secretary. To the extent
that any notice provided constitutes, or contains, material, non-public information regarding the Company, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K.

 

    	 	8	 

     

    

 

g) Successors
and Assigns. This Warrant is part of a unit, each unit consisting of one Series 1 Warrant and one share of Series 1 Preferred.
This Warrant is neither detachable from the Series 1 Preferred nor separately transferable. The provisions of this Warrant
are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder
of Warrant Shares.

 

h)
Amendment. This Warrant may be modified or amended by the Company in its sole discretion for correction of typographical
errors. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder. This Warrant also may be modified or amended or the provisions hereof waived with the written consent of the Company and
the holders of Warrants representing a majority of the Warrant Shares issuable under Warrants then outstanding as of the date
such consent is sought; provided, however, that (i) no such amendment shall adversely affect any Holder differently than it affects
all other Holders, unless such Holder consents thereto and (ii) no amendment may increase the Exercise Price, decrease the number
of shares or class of shares obtainable upon exercise of this Warrant or decrease the time period in which this Warrant can be
exercised without the written consent of the Holder.

 

i)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

j)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

k)
Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and
conditions contained herein.

 

********************

 

(Signature
Page Follows)

 

    	 	9	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	CHANTICLEER HOLDINGS, Inc.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	 	10	 

     

    

 

NOTICE
OF EXERCISE

 

To:
CHANTICLEER HOLDINGS, INC.

 

(1)
The undersigned hereby elects to purchase ________ (increments of ten (10) only) Warrant Shares of the Company pursuant to the
terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together
with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
the cancellation of such number of Series 1 Preferred as is necessary with respect to the maximum number of Warrant Shares purchasable
hereunder, in increments of ten (10) Warrant Shares.

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 	 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

	 	 	 

 

	 	 	 

 

	 	 	 

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ___________________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _____________________________________________________

 

Name
of Authorized Signatory: _______________________________________________________________________

 

Title
of Authorized Signatory: ________________________________________________________________________

 

Date:
___________________________________________________________________________________________SEC Connect

 

Exhibit 4.2

 

AMENDMENT NO. 3 TO

CONVERTIBLE PROMISSORY NOTE

OF

FLUOROPHARMA MEDICAL, INC.

 

THIS
AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA
MEDICAL, INC. (this “Amendment”), dated as of November
__, 2016, is made by FluoroPharma Medical, Inc., a Nevada
corporation (the “Company” or the
“Borrower”), and the undersigned holders (each, a
“Holder” and, collectively, the “Holders”).
The Company and the Holders are sometimes referred to individually
as “Party” and collectively as the
“Parties”.

RECITALS

WHEREAS, the
Company and the Holders entered into a Note and Warrant Purchase
Agreement commencing on MM/DD/YY, as amended (the
“Purchase
Agreement”) pursuant to which the Company issued
convertible promissory notes, as amended (the “Notes”) to the
Holders;

            WHEREAS,
the Notes may be amended only by a written instrument executed by
the Company and the Holders holding a majority of the aggregate
principal amount of the Notes; and

   
        WHERAS, the Holders hold a
majority of the aggregate principal amount of the Notes outstanding
as of the date hereof; and

            WHEREAS,
the Company and the Holders desire to amend certain provisions of
the Note, as amended by this Amendment, as described
herein;

   
        NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties, intending to be legally bound,
hereby agree as follows:

AMENDMENT

1. Capitalized Terms. Capitalized
terms used but not defined herein shall have the meanings ascribed
to such terms in the Note.

2. Amendments to
Note.

(a) The Maturity Date
as defined in the first paragraph of the Notes shall be deleted and
extended by an additional six months such that
“MM/DD/YY” shall be substituted in lieu
thereof.

3. Ratification. Except as
expressly amended hereby, all of the terms, provisions and
conditions of the Note are hereby ratified and confirmed in all
respects by each Party hereto and, except as expressly amended
hereby, are, and hereafter shall continue, in full force and
effect.

4. Entire Agreement. This
Amendment, Amendment No. 2 to the Notes, Amendment No.1 to the
Notes and the Notes and Purchase Agreement (as may have been
amended) constitute the entire agreement of the Parties with
respect to the subject matter hereof and supersede all prior and
contemporaneous agreements and understandings, both written and
oral, between the Parties with respect thereto.

5. Conflicting Terms. In the event
of any inconsistency or conflict between the Note and this
Amendment, the terms, conditions and provisions of this Amendment
shall govern and control.

6. Amendments. No amendment,
supplement, modification or waiver of this Amendment shall be
binding unless executed in writing by all Parties
hereto.

7. Counterparts. This Amendment
may be executed in two or more counterparts, each of which shall
constitute an original but all of which when taken together shall
constitute but one contract.

8. Governing Law. This Amendment
shall be governed by and construed in accordance with the internal
laws of the State of New York, without giving effect to the choice
of law provisions.

9. Successors and Assigns. This
Amendment shall be binding upon and inure to the benefit of the
Parties hereto and their respective permitted successors and
assigns.

 

[Signature pages follow]

 

 

 

IN WITNESS
WHEREOF, the parties hereto
have executed this Amendment No. 3 to Promissory Note as of the
date set forth above. 

   
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
      

   
           
           
           
    

	
 

	
COMPANY:

	
 

	
 

	
 

	
 

FLUOROPHARMA MEDICAL, INC.

	
 

	
 

	
 

	
By:
 

	
 

	
Name: Thomas H.
Tulip

	
 

	
Title: CEO and
President

	
 

	
 

	
 

	
HOLDER:

	
 

	
 

	
 

	
By:

	
 

	
Name:

	
 

	
Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]